Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

PubWeight™: 1.13‹?› | Rank: Top 10%

🔗 View Article (PMC 3466469)

Published in Int Rev Immunol on January 01, 2009

Authors

Thorsten Demberg1, Marjorie Robert-Guroff

Author Affiliations

1: Vaccine Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.

Associated clinical trials:

Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63 | NCT00369031

Reactogenicity and Immunogenicity of Vaginal CNgp140 (SG06RS02) | NCT00637962

Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers | NCT00062530

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects | NCT00001053

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers. | NCT00000846

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers | NCT00000884

Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers | NCT00122564

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects | NCT00000798

Articles citing this

Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53

Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog (2010) 1.16

Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS (2010) 1.11

A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol (2011) 1.06

GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One (2010) 1.01

Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med (2016) 0.98

Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine (2012) 0.94

Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92

CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS One (2011) 0.89

Update on animal models for HIV research. Eur J Immunol (2009) 0.89

Methods for evaluation of humoral immune responses in human genital tract secretions. Am J Reprod Immunol (2010) 0.89

IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology (2014) 0.88

Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clin Immunol (2014) 0.87

Broad-spectrum antiviral therapeutics. PLoS One (2011) 0.85

Evaluation of a quantitative real-time PCR assay to measure HIV-specific mucosal CD8+ T cell responses in the cervix. PLoS One (2010) 0.84

Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses. PLoS One (2013) 0.84

Rhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures. Vaccine (2013) 0.84

A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83

Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. J Virol (2013) 0.82

Characterization of an effective CTL response against HIV and SIV infections. J Biomed Biotechnol (2011) 0.82

Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women. Am J Reprod Immunol (2014) 0.78

Challenges in mucosal HIV vaccine development: lessons from non-human primate models. Viruses (2014) 0.76

Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut. J Immunol (2015) 0.76

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis (2016) 0.75

An effective vaccination approach augments anti-HIV systemic and vaginal immunity in mice with decreased HIV-1 susceptible α4β7high CD4+ T cells. Curr HIV Res (2013) 0.75

Articles cited by this

(truncated to the top 100)

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55

Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11

Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review. PLoS Med (2007) 7.94

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36

Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92

Mucosal immunity and vaccines. Nat Med (2005) 5.44

Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31

HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01

Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41

Dendritic cells in intestinal immune regulation. Nat Rev Immunol (2008) 4.20

Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75

Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66

Oral tolerance. Immunol Rev (2005) 3.48

Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol (1989) 3.43

Mucosal dendritic cells. Annu Rev Immunol (2007) 3.26

Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25

Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04

Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med (2005) 3.02

T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol (2006) 2.94

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72

HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS (2008) 2.67

Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol (2008) 2.58

Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57

Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol (2007) 2.47

Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol (2002) 2.46

DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med (2004) 2.38

Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol (2004) 2.30

A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25

Induction of secretory immunity and memory at mucosal surfaces. Vaccine (2006) 2.24

Adenovirus vaccines in the U.S. military. Mil Med (1995) 2.15

HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol (2006) 2.10

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev (2005) 2.07

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06

Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses (2008) 2.04

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89

Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev (2007) 1.86

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83

HIV vaccines: new frontiers in vaccine development. Clin Infect Dis (2006) 1.82

Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol (2002) 1.72

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine (2007) 1.72

Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis (1998) 1.71

HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005. J Acquir Immune Defic Syndr (2008) 1.68

The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol (2007) 1.65

Prevention with HIV-seropositive men who have sex with men: lessons from the Seropositive Urban Men's Study (SUMS) and the Seropositive Urban Men's Intervention Trial (SUMIT). J Acquir Immune Defic Syndr (2004) 1.65

The use of rectal douches among HIV-uninfected and infected men who have unprotected receptive anal intercourse: implications for rectal microbicides. AIDS Behav (2007) 1.61

Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A (2008) 1.61

Homing to suppress: address codes for Treg migration. Trends Immunol (2005) 1.56

Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today (1999) 1.56

Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol (2005) 1.54

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood (2005) 1.54

Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol (2005) 1.54

A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine (2006) 1.48

Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception (2004) 1.47

The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood (2008) 1.45

Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol (2007) 1.42

Bronchus- and nasal-associated lymphoid tissues. Immunol Rev (2005) 1.42

Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol Med (2007) 1.41

Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41

Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. J Immunol (2007) 1.41

Lung epithelium as a sentinel and effector system in pneumonia--molecular mechanisms of pathogen recognition and signal transduction. Respir Res (2006) 1.39

Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. Inflamm Bowel Dis (2008) 1.38

Entry of viruses through the epithelial barrier: pathogenic trickery. Nat Rev Mol Cell Biol (2003) 1.36

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2007) 1.36

Viral piracy: HIV-1 targets dendritic cells for transmission. Curr HIV Res (2006) 1.35

Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol (2008) 1.35

The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol (2007) 1.34

Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med (2004) 1.34

Chemical adjuvants for plasmid DNA vaccines. Vaccine (2007) 1.34

Drug transfer through mucus. Adv Drug Deliv Rev (2001) 1.32

High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect (2006) 1.29

Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol (2007) 1.28

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol (2004) 1.28

Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med (2008) 1.27

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology (2006) 1.26

Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol (2006) 1.25

Nested case-control study of cervical mucosal lesions, ectopy, and incident HIV infection among women in Cape Town, South Africa. Sex Transm Dis (2006) 1.25

Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology (2003) 1.23

Proteomic analysis of human cervico-vaginal fluid. J Proteome Res (2007) 1.23

Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol (2008) 1.22

Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2002) 1.21

Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood (2003) 1.20

T-cell activation in the intestinal mucosa. Immunol Rev (2007) 1.20

The highway code of T cell trafficking. J Pathol (2008) 1.19

Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med (2005) 1.19

Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2008) 1.18

Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood (2007) 1.16

Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol (2008) 1.15

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol (2006) 1.15

A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines (2004) 1.11

The function of simian chemokine receptors in the replication of SIV. Semin Immunol (1998) 1.11

Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol (2005) 1.09

Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine (2007) 1.08

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine (2007) 1.08

Articles by these authors

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol (2009) 1.93

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2010) 1.91

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83

The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol (2008) 1.72

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol (2011) 1.52

Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol (2012) 1.48

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2007) 1.36

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol (2005) 1.27

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology (2006) 1.26

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol (2006) 1.22

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr (2006) 1.21

Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol (2003) 1.16

Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine (2011) 1.16

Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13

A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines (2004) 1.11

TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol (2011) 1.11

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine (2007) 1.08

Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol (2012) 1.07

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine (2008) 1.05

Adenoviruses as vectors for HIV vaccines. AIDS Rev (2003) 1.04

A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol (2003) 1.03

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol (2003) 1.02

Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01

Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00

Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol (2012) 0.99

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine (2003) 0.99

Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs (2007) 0.98

Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology (2008) 0.96

Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol (2010) 0.93

Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92

A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology (2011) 0.91

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res (2013) 0.90

NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol (2012) 0.89

Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology (2011) 0.89

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol (2010) 0.88

Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge. J Virol (2008) 0.88

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine (2006) 0.88

Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology (2005) 0.87

Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol (2011) 0.86

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85

Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. AIDS Res Hum Retroviruses (2011) 0.83

Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology (2013) 0.83

Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res Hum Retroviruses (2004) 0.83

Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology (2013) 0.83

Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J Virol (2002) 0.82

Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS (2006) 0.82

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol (2002) 0.81

Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine (2011) 0.81

Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol (2005) 0.81

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine (2010) 0.80

High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS (2012) 0.79

Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. PLoS One (2013) 0.79

Live recombinant vectors for AIDS vaccine development. Curr Mol Med (2003) 0.79

Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology (2002) 0.79

Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques. Immunology (2015) 0.77

Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS. J Virol (2013) 0.77

Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses (2015) 0.77

High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge. PLoS One (2013) 0.76

Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med (2016) 0.75

Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques. J Med Primatol (2002) 0.75